Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Shanghai Bao Pharmaceuticals Co's goodwill for the quarter that ended in Dec. 2025 was HK$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Shanghai Bao Pharmaceuticals Co Goodwill Related Terms
Shanghai Bao Pharmaceuticals Co Goodwill Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Bao Pharmaceuticals Co Goodwill Calculation
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a Goodwill of HK$0.00 Mil as of Dec. 2025. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors.
Is Shanghai Bao Pharmaceuticals Co's Goodwill too high?
Shanghai Bao Pharmaceuticals Co's current Goodwill is HK$0.00 Mil. Overall, Shanghai Bao Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Bao Pharmaceuticals Co's Goodwill compare to VRTX and REGN?
Shanghai Bao Pharmaceuticals Co's Goodwill of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill for a Biotechnology company?
A good Goodwill depends on the Biotechnology industry context. However, Goodwill should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill mean?
A high Goodwill can signal that a stock is expensive relative to its fundamentals. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. Shanghai Bao Pharmaceuticals Co's current Goodwill is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Bao Pharmaceuticals Co stock overvalued right now?
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a current Goodwill of HK$0.00 Mil. The current Goodwill is HK$0.00 Mil. Shanghai Bao Pharmaceuticals Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill calculated?
Goodwill is calculated from a company's financial statements. For Shanghai Bao Pharmaceuticals Co (HKSE:02659), the current Goodwill is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai Bao Pharmaceuticals Co Ltd is a biotechnology company with an approved product and a diverse clinical pipeline, leveraging synthetic biology technology to develop and deliver recombinant biologic drugs in China, targeting conditions with limited treatment options and complex manufacturing challenges. The company has proprietary technology platforms, supported by its chassis cell engineering technology, that combine drug design and bioprocessing capabilities. It has production lines for finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes. The group has only one reportable operating segment, which is the research, development, and commercialisation of pharmaceutical products.
9GF Score
Get the complete analysis for HKSE:02659
Goodwill is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02659 has been successfully added to your 
